Halberd’s Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation Jackson Center, PA, April 30, 2024 – Halberd Corporation (OTC-PINK: "HALB”) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot ...